Difference between revisions of "Staging page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Blanked the page)
Tag: Blanking
 
(35 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
<span id="BackToTop"></span>
+
 
−
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
 
−
[[#top|Back to Top]]
 
−
</div>
 
−
{| class="wikitable" style="text-align:center; width:50%;"
 
−
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
 
−
|-
 
−
|style="background-color:#F0F0F0"|[[File:Sanjay_mohan.png|frameless|upright=0.3|center]]
 
−
|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Vanderbilt University<br>Nashville, TN</big>
 
−
|-
 
−
|}
 
−
{| class="wikitable" style="float:right; margin-right: 5px;"
 
−
|-
 
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
 
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
−
|}
 
−
{{TOC limit|limit=3}}
 
−
=Guidelines=
 
−
==NCCN==
 
−
*[https://www.nccn.org/professionals/physician_gls/pdf/mlne.pdf NCCN Guidelines - Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes]
 
−
=All lines of therapy=
 
−
==Alemtuzumab monotherapy {{#subobject:9207db|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:45d126|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.jacionline.org/article/S0091-6749(09)00223-1 Wagner et al. 2009]
 
−
|style="background-color:#ffffbe"|Case report
 
−
|-
 
−
|}
 
−
''Note: treatment is to be given bi-weekly, exact days not specified; below is an example. Duration also not specified.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Alemtuzumab (Campath)]] 30 mg IV once per day on days 1 & 4
 
−
'''7-day cycles'''
 
−
</div></div>
 
−
===References===
 
−
# '''Case report:''' Wagner LA, Speckart S, Cutter B, Gleich GJ. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. J Allergy Clin Immunol. 2009 Jun;123(6):1407-8. Epub 2009 Apr 1. [http://www.jacionline.org/article/S0091-6749(09)00223-1 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/19342084 PubMed]
 
−
# '''Retrospective:''' Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):287-91. Epub 2012 Nov 1. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(12)00202-9 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445419/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23123105 PubMed]
 
−
==Benralizumab monotherapy {{#subobject:39b68c|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:2gh77d|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557265/ Kuang et al. 2019 (NIAID 14-I-0081)]
 
−
|2014-2017
 
−
| style="background-color:#91cf61" |Randomized Phase 2, <20 pts (E-esc)
 
−
|[[#Placebo_88|Placebo]]
 
−
| style="background-color:#91cf60" |Seems to have superior primary endpoint
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Immunosuppressive therapy====
 
−
*[[Benralizumab (Fasenra)]] 30 mg SC once on day 1
 
−
'''28-day cycle for 6 or more cycles'''
 
−
</div></div>
 
−
===References===
 
−
# '''NIAID 14-I-0081:''' Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019 Apr 4;380(14):1336-1346. [https://doi.org/10.1056/NEJMoa1812185 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557265/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30943337 PubMed] NCT00001406
 
−
==Cladribine & Cytarabine {{#subobject:b80308|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:d51fc2|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1002/cncr.21186 Jabbour et al. 2005]
 
−
|style="background-color:#ffffbe"|Phase 2, <20 pts
 
−
|-
 
−
|}
 
−
''Note: the timing of drug administration is in hours in the manuscript, starting at t = 0 hours.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cladribine (Leustatin)]] 12 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 2 (total dose: 60 mg/m<sup>2</sup>)
 
−
*[[Cytarabine (Ara-C)]] 1000 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 3, 4, 5, 6
 
−
'''21-day cycle, repeated once if PR/CR; see text for definition of PR'''
 
−
</div></div>
 
−
===References===
 
−
# Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 1;104(3):541-6. [https://doi.org/10.1002/cncr.21186 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15977212 PubMed]
 
−
==Hydroxyurea monotherapy {{#subobject:e819ce|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:4e5567|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.7326/0003-4819-89-2-167 Parrillo et al. 1978]
 
−
|style="background-color:#ffffbe"|Non-randomized, <20 pts
 
−
|-
 
−
|}
 
−
''Note: treatment details are not available in the abstract.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Hydroxyurea (Hydrea)]]
 
−
</div></div>
 
−
===References===
 
−
# Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978 Aug;89(2):167-72. [https://doi.org/10.7326/0003-4819-89-2-167 link to original article] [https://pubmed.ncbi.nlm.nih.gov/677578 PubMed]
 
−
==Imatinib monotherapy {{#subobject:77c7b0|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:0be8cc|Variant=1}}===
 
−
{| class="wikitable" style="color:white; background-color:#404040"
 
−
|<small>'''FDA-recommended dose'''</small>
 
−
|-
 
−
|}
 
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 
−
!style="width: 33%"|Study
 
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1016/S0140-6736(02)08505-7 Gleich et al. 2002]
 
−
|NR in abstract
 
−
|style="background-color:#ffffbe"|Non-randomized, <20 pts
 
−
|-
 
−
|[https://doi.org/10.1056/NEJMoa020150 Apperley et al. 2002 (STIB2225)]
 
−
|NR
 
−
|style="background-color:#ffffbe"|Phase 2, <20 pts
 
−
|-
 
−
|[http://www.bloodjournal.org/content/101/9/3391.long Pardanani et al. 2002]
 
−
|NR
 
−
|style="background-color:#ffffbe"|Phase 2, <20 pts
 
−
|-
 
−
|[http://www.bloodjournal.org/content/101/12/4714.long Cortes et al. 2003]
 
−
|2001-2002
 
−
|style="background-color:#ffffbe"|Phase 2, <20 pts
 
−
|-
 
−
|[https://doi.org/10.1056/NEJMoa025217 Cools et al. 2003]
 
−
|2001-2002
 
−
|style="background-color:#ffffbe"|Non-randomized, <20 pts
 
−
|-
 
−
|[http://www.haematologica.org/content/92/9/1173.long Baccarani et al. 2007]
 
−
|2001-2007
 
−
|style="background-color:#91cf61"|Phase 2
 
−
|-
 
−
|[http://www.bloodjournal.org/content/103/2/473.long Klion et al. 2003]
 
−
|2003
 
−
|style="background-color:#ffffbe"|Non-randomized, <20 pts
 
−
|-
 
−
|[https://doi.org/10.1111/j.1365-2141.2008.07033.x Helbig et al. 2008]
 
−
|NR
 
−
|style="background-color:#ffffbe"|Non-randomized, <20 pts
 
−
|-
 
−
|[https://doi.org/10.1111/j.1365-2141.2008.07294.x Metzgeroth et al. 2008]
 
−
|NR
 
−
|style="background-color:#91cf61"|Phase 2
 
−
|-
 
−
|}
 
−
''Note: Dosing is as described in the Metzgeroth et al. 2008 paper.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Imatinib (Gleevec)]] by the following mutation-specific criteria:
 
−
**FIP1L1-PDGFRA positive patients: 100 mg PO once per day
 
−
**PDGFRB fusion positive or without known molecular aberration: 400 mg PO once per day
 
−
'''28-day cycle for 13 or more cycles'''
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*Helbig et al. 2008: Patients proceeded to a maintenance phase after 3 to 6 months of therapy which consisted of weekly dosing; dose not specified in the manuscript
 
−
</div></div>
 
−
===References===
 
−
# Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002 May 4;359(9317):1577-8. [https://doi.org/10.1016/S0140-6736(02)08505-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12047970 PubMed]
 
−
# '''STIB2225:''' Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002 Aug 15;347(7):481-7. [https://doi.org/10.1056/NEJMoa020150 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/12181402 PubMed]
 
−
## '''Pooled update:''' Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, Gimelfarb A, Cross NC, Seymour JF. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014 Jun 5;123(23):3574-7. Epub 2014 Mar 31. [http://www.bloodjournal.org/content/123/23/3574.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047496/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24687085 PubMed]PubMed PMID: 24687085
 
−
# Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003 May 1;101(9):3391-7. Epub 2002 Dec 27. [http://www.bloodjournal.org/content/101/9/3391.long link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/12506022 PubMed]
 
−
# Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003 Jun 15;101(12):4714-6. Epub 2003 Feb 20. [http://www.bloodjournal.org/content/101/12/4714.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12595304 PubMed]
 
−
# Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27;348(13):1201-14. [https://doi.org/10.1056/NEJMoa025217 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/12660384 PubMed]
 
−
# Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004 Jan 15;103(2):473-8. Epub 2003 Sep 22. [http://www.bloodjournal.org/content/103/2/473.long link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/14504092 PubMed]
 
−
# Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome: results of a multicenter prospective study. Haematologica. 2007 Sep;92(9):1173-9. Epub 2007 Aug 1. [http://www.haematologica.org/content/92/9/1173.long link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/17666373 PubMed] NCT00276929
 
−
# Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol. 2008 Apr;141(2):200-4. Epub 2008 Feb 26. [https://doi.org/10.1111/j.1365-2141.2008.07033.x link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/18307562 PubMed]
 
−
# Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NC, Hehlmann R, Hochhaus A, Reiter A. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008 Dec;143(5):707-15. Epub 2008 Oct 17. [https://doi.org/10.1111/j.1365-2141.2008.07294.x link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18950453 PubMed]
 
−
==Mepolizumab monotherapy {{#subobject:39b7a4|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:2ef22d|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Years of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJMoa070812 Rothenberg et al. 2008 (GSK 100185)]
 
−
|2004-2006
 
−
| style="background-color:#1a9851" |Phase 3 (E-esc)
 
−
|[[#Placebo_88|Placebo]]
 
−
| style="background-color:#1a9850" |Superior primary endpoint
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Immunosuppressive therapy====
 
−
*[[Mepolizumab (Nucala)]] 750 mg IV once on day 1
 
−
'''21-day cycle for 8 cycles'''
 
−
</div></div>
 
−
===References===
 
−
# '''GSK 100185:''' Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530. [https://doi.org/10.1056/NEJMoa070812 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18344568 PubMed] NCT00086658
 
−
## '''Update:''' Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. Epub 2012 Oct 4. [https://doi.org/10.1016/j.jaci.2012.07.055 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23040887 PubMed]
 
−
==Nilotinib monotherapy {{#subobject:007581|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:267a4e|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1056/NEJMoa055104 Kantarjian et al. 2006 (A2101)]
 
−
|style="background-color:#ffffbe"|Phase 1/2, <20 pts of this subtype
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Nilotinib (Tasigna)]] 400 mg PO twice per day
 
−
</div></div>
 
−
===References===
 
−
# '''A2101:''' Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51. [https://doi.org/10.1056/NEJMoa055104 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16775235 PubMed] NCT00109707
 
−
## '''Subgroup analysis:''' Hochhaus A, le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol. 2013 Dec;139(12):1985-93. Epub 2013 Sep 22. [http://link.springer.com/article/10.1007/s00432-013-1529-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24057647 PubMed]
 
−
==Peginterferon alfa-2a monotherapy {{#subobject:010d91|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:72ed60|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://www.lrjournal.com/article/S0145-2126(11)00469-3 Butterfield et al. 2011]
 
−
|style="background-color:#ffffbe"|Case series
 
−
|-
 
−
|}
 
−
''Note: The authors describe using peginterferon alfa-2b initially but switched to peginterferon alfa-2a when the first was "no longer available. Dosing details are not available in the abstract."
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Immunotherapy====
 
−
*[[Peginterferon alfa-2a (Pegasys)]]
 
−
</div></div>
 
−
===References===
 
−
# '''Case series:''' Butterfield JH, Weiler CR. Use of pegylated interferon in hypereosinophilic syndrome. Leuk Res. 2012 Feb;36(2):192-7. Epub 2011 Nov 26. [http://www.lrjournal.com/article/S0145-2126(11)00469-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22118911 PubMed]
 
−
==Ruxolitinib monotherapy {{#subobject:87790c|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:f86a11|Variant=1}}===
 
−
{| class="wikitable" style="width: 40%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://doi.org/10.1200/jco.2012.46.4370 Rumi et al. 2013]
 
−
|style="background-color:#ffffbe"|Case report
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Targeted therapy====
 
−
*[[Ruxolitinib (Jakafi)]] 15 mg PO twice per day
 
−
'''Duration not specified'''
 
−
</div></div>
 
−
===References===
 
−
# '''Case report:''' Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, Boni M, Bernasconi P, Passamonti F, Kralovics R, Cazzola M. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013 Jun 10;31(17):e269-71. Epub 2013 Apr 29. [https://doi.org/10.1200/jco.2012.46.4370 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/23630205 PubMed]
 
−
[[Category:Hypereosinophilic syndrome regimens]]
 
−
[[Category:Disease-specific pages]]
 
−
[[Category:Myeloproliferative neoplasms]]
 
−
[[Category:Clinical pharmacology]]
 

Latest revision as of 00:13, 18 June 2023

Retrieved from "https://hemonc.org/w/index.php?title=Staging_page&oldid=73776"